Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 15/20 | 0.40 |
| ▸ | GIPR | P48546 | 14/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585824 | 0.92 | GCGR (0.40) | GCGRGIPRALOX5PTGESMEN1 | |
| SCHEMBL5585770 | 0.88 | GCGR (0.50) | GCGRGIPR | |
| SCHEMBL5585451 | 0.88 | GCGR (0.45) | GCGRGIPRALOX5PTGESMEN1 | |
| SCHEMBL5585478 | 0.81 | MRE11 (0.39) | GCGRGIPRMEN1ALDH1A1LMNA | |
| SCHEMBL5585653 | 0.78 | RAB9A (0.41) | GCGRGIPRMEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL5585772 | 0.78 | RAB9A (0.40) | GCGRGIPRMEN1ALDH1A1LMNA | |
| SCHEMBL5585688 | 0.78 | RAB9A (0.40) | GCGRGIPRMEN1ALDH1A1LMNA | |
| SCHEMBL5585837 | 0.78 | HDAC3 (0.48) | GCGRGIPRALOX5PTGESMEN1 | |
| SCHEMBL5585652 | 0.77 | GCGR (0.50) | GCGRGIPRMAPT | |
| SCHEMBL5585527 | 0.77 | KDM4E (0.45) | GCGRGIPRPTGESMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | GCGR 317/4885GIPR 195/4885ALOX5 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.